title: A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.
abstract: BACKGROUND
  Centrosome aberrations can cause genomic instability and correlate with malignant progression in common human malignancies such as breast and prostate cancer. Deregulation of cyclin/cyclin-dependent kinase 2 (CDK2) activity has previously been shown to be critically involved in centrosome overduplication. We therefore test here whether small molecule CDK inhibitors derived from the bis-indole indirubin can be used to suppress centrosome aberrations as a novel approach to chemoprevention of malignant progression.
  
  
  RESULTS
  As expected, we found that the CDK inhibitor indirubin-3'-oxime (IO) suppresses centrosome amplification in breast cancer cells. However, we made the unexpected discovery that indirubin-derived compounds that have been chemically modified to be inactive as kinase inhibitors such as 1-methyl-indirubin-3'-oxime (MeIO) still significantly reduced centrosome amplification. All indirubins used in the present study are potent agonists of the aryl hydrocarbon receptor (AhR), which is known for its important role in the cellular metabolism of xenobiotics. To corroborate our results, we first show that the coincidence of nuclear AhR overexpression, reflecting a constitutive activation, and numerical centrosome aberrations correlates significantly with malignancy in mammary tissue specimens. Remarkably, a considerable proportion (72.7%) of benign mammary tissue samples scored also positive for nuclear AhR overexpression. We furthermore provide evidence that continued expression of endogenous AhR is critical to promote centriole overduplication induced by cyclin E and that AhR and cyclin E may function in the same pathway. Overexpression of the AhR in the absence of exogenous ligands was found to rapidly disrupt centriole duplication control. Nonetheless, the AhR agonists IO and MeIO were still found to significantly reduce centriole overduplication stimulated by ectopic AhR expression.
  
  
  CONCLUSIONS
  Our results indicate that continued expression of endogenous AhR promotes centrosome amplification in breast cancer cells in a pathway that involves cyclin E. AhR agonists such as indirubins inhibit centrosome amplification even when stimulated by ectopic expression of the AhR suggesting that these compounds are potentially useful for the chemoprevention of centrosome-mediated cell division errors and malignant progression in neoplasms in which the AhR is overexpressed. Future studies are warranted to determine whether individuals in which nuclear AhR overexpression is detected in benign mammary tissue are at a higher risk for developing pre-cancerous or cancerous breast lesions.
authors.affiliation: Cancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
authors.forename: Nina
authors.initials: N
authors.lastname: Korzeniewski
authors.forename: Sarah
authors.initials: S
authors.lastname: Wheeler
authors.forename: Payel
authors.initials: P
authors.lastname: Chatterjee
authors.forename: Anette
authors.initials: A
authors.lastname: Duensing
authors.forename: Stefan
authors.initials: S
authors.lastname: Duensing
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology / Q000517:prevention & control; D045744:Cell Line, Tumor; D018385:Centrosome; D018890:Chemoprevention; D005260:Female; D006801:Humans; D034741:RNA, Small Interfering; D018336:Receptors, Aryl Hydrocarbon / Q000502:physiology*
chemical_list: D034741:RNA, Small Interfering; D018336:Receptors, Aryl Hydrocarbon